IDEAYA Biosciences had its Relative Strength (RS) Rating upgraded from 79 to 82 Tuesday.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an RS Rating of over 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
IDEAYA Biosciences is now considered extended and out of buy range after clearing a 30.25 buy point in a third-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
IDEAYA Biosciences reported 0% EPS growth in the latest quarterly report, while sales growth came in at -100%.
The company holds the No. 197 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
